Fraser Wright, PhD

Fraser Wright is the Scientific Co-Founder and Chief Gene Therapy Officer (CGTO) at Kriya. Prior to becoming CGTO in 2024, Fraser was Kriya’s Chief Technology Advisor. During his career he has contributed to numerous gene therapy development programs, including those leading to the regulatory approvals of multiple FDA approved commercial products: Luxturna^® for RPE65-/- Leber congenital amarosis Type 2, the first gene therapy for a genetic disease; Kymriah^®, the first CAR T‑cell therapy for lymphoma and leukemia indications; and Beqvez^™ for the treatment of hemophilia B. Prior to becoming the CGTO, Fraser was a Professor of Pediatrics in the Center for Definitive and Curative Medicine at Stanford University. He was also the co-founder and Chief Technology Officer of Spark Ther­a­peu­tics. Prior to co-founding Spark Ther­a­peu­tics, he was the founding Scientific Director of the Clinical Vector Core Laboratory at the Children’s Hospital of Philadel­phia. He was also previously the director of development and clinical man­u­fac­tur­ing at Avigen. Fraser received his PhD in bio­chem­istry and molecular immunology and his under­grad­u­ate degree in bio­chem­istry and physiology from the University of Toronto.